Children in the Caffeine for Apnea of Prematurity trial were assessed for motor performance ( Movement Assessment Battery for Children [ MABC ] ) , clinical signs of cerebral palsy , and Full-Scale IQ at 5 years of age by staff who were unaware of the children 's treatment group .